Clinical Trials
8 trialsNCT05114746 2026-05-08
Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan
Novartis
Phase 2 Completed
NCT04443062 2026-02-27
Bullseye
Radboud University Medical Center
Phase 2 Completed
NCT05162573 2025-12-10
PROQURE-1
The Netherlands Cancer Institute
Phase 1 Completed
NCT06461689 2025-03-04
PROLUT
Central Hospital, Nancy, France
Completed
NCT03805594 2025-02-25
177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
University of California, San Francisco
Phase 1 Completed
NCT03511664 2025-01-13
VISION
Endocyte
Phase 3 Completed
NCT03392428 2022-06-13
TheraP
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Phase 2 Completed
NCT03828838 2019-11-14
Lutetium-177-PSMA-617 in Low Volume Metastatic Prostate Cancer
Radboud University Medical Center
Phase 1/2 Completed